Women's Health Information for Grant Submissions
Bayer funds educational programs for healthcare professionals on menopause symptom management, emphasizing neurokinin-targeted therapies and the KNDy system’s role in vasomotor symptoms.
Funder: Bayer
Due Dates: Rolling monthly review (allow 45 days for response)
Funding Amounts: Not specified; funding varies by educational program scope and budget.
Summary: Supports educational initiatives for healthcare professionals on menopause symptom management, emphasizing neurokinin-targeted therapies and related systems.
Key Information: Applications must be submitted online and comply with commercial support standards; responses take at least 45 days.
Description
This grant opportunity from Bayer supports healthcare professionals and organizations in advancing education on menopause symptom management, with a particular focus on neurokinin-targeted therapies (NKT) and the KNDy system's role in vasomotor symptoms such as sleep and mood disturbances. The program aims to expand awareness of hormonal versus nonhormonal treatments, address the systemic impacts of untreated menopause symptoms, and educate on the safety and efficacy of various treatment options. Special emphasis is placed on the hypothesized roles of Neurokinin 1 (NK1) and Substance P in sleep disturbances, as well as the benefits of NKT therapies for oncology patients experiencing vasomotor symptoms due to endocrine therapy. The grant encourages development of enduring educational materials, downloadable slides, social media outreach, podcasts, and live virtual formats.
